Founded with the mission to accelerate the discovery, commercialization, and access to cancer immunotherapy, C3i is a comprehensive Contract Development and Manufacturing Organization (CDMO). The company specializes in process development and Good Manufacturing Practice (GMP) manufacturing, focusing on innovative cancer treatments. C3i aims to bridge the gap between groundbreaking research and market-ready therapies, providing end-to-end solutions for biotech companies and research institutions.
C3i has garnered attention for its contributions to the field of cancer immunotherapy, collaborating with leading researchers and biotech firms. The organization has achieved significant milestones in advancing therapeutic candidates from the lab to clinical trials. By streamlining the commercialization process, C3i has had a notable impact on making advanced cancer treatments more accessible, thereby enhancing patient outcomes and driving innovation in oncology.
